As filed with the Securities and Exchange Commission December 22, 2022
Registration No. 33-23053
Registration No. 33-38030
Registration No. 33-65192
Registration No. 333-38865
Registration No. 333-66029
Registration No. 333-103245
Registration No. 333-114066
Registration No. 333-123675
Registration No. 333-123676
Registration No. 333-132054
Registration No. 333-152989
Registration No. 333-176620
Registration No. 333-186613
Registration No. 333-206395
Registration No. 333-209414
Registration No. 333-213319
Registration No. 333-227226
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Post-Effective Amendment No. 3 to Form S-8 Registration Statement No. 33-23053
Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 33-38030
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 33-65192
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-38865
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-66029
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-103245
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-114066
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-123675
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-123676
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-132054
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-152989
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-176620
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-186613
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-206395
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-209414
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-213319
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-227226
UNDER
THE SECURITIES ACT OF 1933
ABIOMED, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 04-2743260 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
22 Cherry Hill Drive
Danvers, Massachusetts 01923
(503) 331-7270
(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)
ABIOMED, Inc. Incentive Stock Option Plan
ABIOMED, Inc. Non-Qualified Stock Option Plan
ABIOMED, Inc. 1992 Combination Stock Option Plan
ABIOMED, Inc. 1989 Non-Qualified Stock Option Plan for Non-Employee Directors
ABIOMED, Inc. 1988 Employee Stock Purchase Plan
ABIOMED, Inc. 1998 Equity Incentive Plan
ABIOMED, Inc. 2000 Stock Incentive Plan
Nonqualified Stock Option Granted by ABIOMED, Inc. to Michael R. Minogue Dated April 5, 2004
ABIOMED Retirement Savings Plan
ABIOMED, Inc. 2008 Stock Incentive Plan
ABIOMED, Inc. Amended and Restated 2008 Stock Incentive Plan
ABIOMED, Inc. Second Amended and Restated 2008 Stock Incentive Plan
ABIOMED, Inc. 2015 Omnibus Incentive Plan
ABIOMED, Inc. Fourth Amended and Restated 2008 Stock Incentive Plan
ABIOMED, Inc. Amended & Restated 2015 Omnibus Incentive Plan
ABIOMED, Inc. Second Amended & Restated 2015 Omnibus Incentive Plan
(Full Title of the Plans)
Michael R. Minogue
Chairman, President and Chief Executive Officer
ABIOMED, Inc.
22 Cherry Hill Drive
Danvers Massachusetts 01923
(Name and Address, including Zip Code, of Agent for Service)
with copies to:
Matthew G. Hurd Sullivan & Cromwell LLP 125 Broad Street New York, New York 10004 (212) 558-3122 |
Robert W. Downes Sullivan & Cromwell LLP 125 Broad Street New York, New York 10004 (212) 558-4312 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☒ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
DEREGISTRATION OF SECURITIES
This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”) previously filed by ABIOMED, Inc., a Delaware Corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”):
• | Registration Statement on Form S-8 (File No. 33-23053), originally filed with the SEC on July 11, 1988, registering 700,000 shares of the Company’s common stock, par value $0.01 per share (“Shares”), issuable in connection with the Company’s Incentive Stock Option Plan, Non-Qualified Stock Option Plan and 1988 Employee Stock Purchase Plan, at a proposed maximum offering price per share of $9.125. (P) |
• | Registration Statement on Form S-8 (File No. 33-38030), which incorporates by reference and serves as Post-Effective Amendment No.1 to Registration Statement No. 33-23053 on Form S-8, originally filed with the SEC on November 30, 1990, registering 350,000 Shares issuable in connection with the Company’s Incentive Stock Option Plan, Non-Qualified Stock Option Plan, 1989 Non-Qualified Stock Option Plan for Non-Employee Directors and 1988 Employee Stock Purchase Plan, at a proposed maximum offering price per share of $5.625. (P) |
• | Registration Statement on Form S-8 (File No. 33-65192), which incorporates by reference and serves as Post-Effective Amendment No. 2 to Registration Statement No. 33-23053 on Form S-8 and Post-Effective Amendment No. 1 to Registration Statement No. 33-38030 on Form S-8, originally filed with the SEC on June 28, 1993, registering 250,000 Shares issuable in connection with the Company’s 1992 Combination Stock Option Plan (formerly known as (1) the Incentive Stock Option Plan and (2) the Non-Qualified Stock Option Plan), at a proposed maximum offering price per share of $8.25. (P) |
• |
• |
• |
• |
• |
-2-
• |
• |
• |
• |
• |
• |
• |
• |
• |
This Post-Effective Amendment is being filed in connection with the closing on December 22, 2022 of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of October 31, 2022 (the “Merger Agreement”), by and among Johnson & Johnson, a New Jersey corporation (“Parent”), Athos Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company. On December 22, 2022, pursuant to the Merger Agreement, Merger Sub was merged with and into the Company (the “Merger”), with the Company surviving the Merger and continuing as a wholly owned subsidiary of Parent.
As a result of the Merger, the Company has terminated all offerings of the Company’s securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, the Company hereby removes from registration all such securities of the Company registered pursuant to the Registration Statements that remain unsold and any plan interests that are unissued as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.
-3-
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Danvers, Commonwealth of Massachusetts, on December 22, 2022. No other person is required to sign this Post-Effective Amendment to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.
ABIOMED, Inc. | ||||
By: | /s/ Andrew Greenfield | |||
Name: | Andrew Greenfield | |||
Title: | Executive Vice President, Chief Commercial Officer |
-4-